Sage Journals: Discover world-class research

Abstract

Acute pancreatitis (AP) is one of the most common acute abdominal conditions, and its incidence has been increasing for years. Approximately 15–20% of patients develop severe AP (SAP), which is complicated by critical inflammatory injury and intestinal dysfunction. AP-associated inflammation can lead to the gut barrier and function damage, causing dysbacteriosis and facilitating intestinal microbiota migration. Pancreatic exocrine deficiency and decreased levels of antimicrobial peptides in AP can also lead to abnormal growth of intestinal bacteria. Meanwhile, intestinal microbiota migration influences the pancreatic microenvironment and affects the severity of AP, which, in turn, exacerbates the systemic inflammatory response. Thus, the interaction between the gut microbiota (GM) and the inflammatory response may be a key pathogenic feature of SAP. Treating either of these factors or breaking their interaction may offer some benefits for SAP treatment. In this review, we discuss the mechanisms of interaction of the GM and inflammation in AP and factors that can deteriorate or even cure both, including some traditional Chinese medicine treatments, to provide new methods for studying AP pathogenesis and developing therapies.

Keywords

acute pancreatitis cell damage factors inflammatory responses intestinal barrier gut microbiota

Introduction

Multiple organ dysfunction may occur during the early phase of severe acute pancreatitis (SAP), resulting in a high fatality rate. However, over time, the patient enters a second stage, which accompanies the infection and is another cause of the high mortality rate of SAP.¹ Studies have shown that most pancreatic and extra-pancreatic organ infections are caused by the translocation of intestinal bacteria; such infections result in pancreatic necrosis and sepsis, causing late death in patients with SAP.² The gut microbiota (GM) is mutualistic with the human body under certain steady states; some gut bacteria can ferment dietary fiber to form short-chain fatty acids (SCFAs), which are then absorbed by the host.³ The intestinal mucosa can also maintain the stability of the intestinal environment through its barrier function. Once this stability is disrupted by a persistent inflammatory response in SAP, this can lead to intestinal mucosal damage and a change in the status of the intestinal microbiota.⁴ Studies have also indicated that various types of intestinal microbiota participate in different pathological conditions, including pancreatic diseases.⁵ The role of the intestinal microbiota in the progression of SAP has gradually been clarified in previous studies.

We have searched articles or other types of manuscripts related to the regulatory mechanism of the intestinal microbiota, inflammation, and pathogenesis of SAP or acute pancreatitis (AP) in PubMed and the China National Knowledge Infrastructure, to describe the interactions between the GM and inflammatory responses in AP. We have identified some new methods of AP pathogenesis and the development of therapies. All of our findings are described in the following chapters.

The influence of intestinal flora changes on the occurrence and development of AP

Intestinal flora migration influences the pancreatic microenvironment in AP

Impairment in microcirculation and blood volume reduction during AP can lead to ischemia and reperfusion damage in the intestinal mucosa, causing loss of intestinal barrier integrity and intestinal bacterial translocation and causing local and systemic infections.^6
–8 Fewer antimicrobials secreted by the pancreas in AP can also lead to bacterial overgrowth in the small intestine, which further disrupts the balance of the intestinal microbiota.⁹ The imbalance of the intestinal microbiota or mucosal damage can increase intestinal permeability, causing the translocation of bacteria from the gut to the blood or nearby tissues, such as the pancreas, increasing the risk of pancreatic infection and aggravating inflammation.¹⁰ A study has found more than one type of bacterial DNA in the peripheral blood of patients with AP, and these DNA molecules are mainly derived from conditional pathogenic bacteria from the gut, such as Escherichia coli, Shigella flexneri, Acinetobacter lwoffii, Bacillus coagulans, and Enterobacter faecalis.¹¹ Thus, the transfer of bacteria from the gut to the blood may cause infection of necrotic parts of the pancreas.

Recent studies have revealed that nucleotide-binding oligomerization domain 1 (NOD1), an intracellular innate immune receptor, plays a critical role in host defense functions and inflammation. This is because NOD1 can detect small peptide components derived from bacterial wall peptidoglycan and can be excited by intestinal bacteria.¹² On the other hand, NOD1 has been reported to activate innate responses and produce nuclear factor-kappa B (NF-κB) and type 1 interferon-inducing pancreatitis and contribute to the development of pancreatitis.^13,14 Thus, NOD1 may be an intermediate regulatory factor of intestinal microbiota interaction with AP.

Previously, the microbial composition of the infected areas of pancreatic necrosis was mainly gram-negative bacteria from the gastrointestinal tract (GIT), such as Enterobacteriaceae. However, recently, Staphylococcus and Enterococcus have become dominant bacteria owing to the widespread use of prophylactic antibiotics.¹⁵ Meanwhile, the prophylactic use of antibiotics does not reduce the risk of infection, and patients with a higher risk of infection in regional pancreatic necrosis are those who have previously received antibiotics.^16,17

Intestinal microbiota attenuates the severity of AP

A normal intestinal microbiota constitutes the intestinal mucosal biological barrier that affects intestinal peristalsis, regulates host immunity, and strengthens the epithelial barrier.¹⁸ Studies have shown that intestinal mucosal barrier damage in patients with AP is closely associated with the imbalance of the intestinal microbiota, for example, increased abundances of the intestinal pathogenic bacteria Shigella and Enterococcus and decreased abundances of the beneficial bacteria Lactobacillus and Blautia.^19
–21 Deng showed that the bacterial translocation rates of E. coli and Bifidobacterium and the pathological damage score of intestinal tissue were significantly higher in the intestines of SAP rats than in those of the control group, suggesting that the intestinal barrier function of SAP rats was impaired, resulting in an intestinal microbiota disorder.²² Moreover, the Acute Physiology and Chronic Health Evaluation (APACHE)-II score, the length of the hospital stay, complications such as infections and the incidence of multiple organ dysfunction syndrome were significantly higher in patients with SAP with a GM imbalance than in individuals with intestinal microbiota ratios similar to those of healthy individuals.⁹

It has been reported that inter-intestinal probiotics mitigated AP severity by inhibiting the activation of the NOD-like receptor family 3 (NLRP3) inflammasome in the gut,^23,24 which might be the mechanism of regulating the intestinal microbiota to reduce the degree of SAP. E. coli has been reported to induce intestinal mucosal barrier damage and aggravate AP through the activation of the toll-like receptor 4 (TLR4), myeloid differentiation factor 88 (MyD88), and p38 mitogen-activated protein kinase (MAPK) signaling pathways.^25,26 Therefore, MAPK inhibitors and TLR4-dependent Phosphoinositide 3-kinase (PI3K), V-akt murine thymoma viral oncogene homolog (AKT), and NF-kB inflammatory signaling pathway inhibitors are important in correcting GM imbalance and mitigating inflammatory responses.^27,28 SCFAs, a metabolite of intestinal bacteria, can not only provide growth energy for intestinal mucosal cells but also regulate intestinal pH, maintain the integrity of tight junction proteins between intestinal mucosal epithelial cells, improve intestinal mucosal barrier function, and significantly reduce the severity of SAP.^21,24,29 On the other hand, Bacteroides, Escherichia–Shigella and Enterococcus, are the major intestinal microbes in AP, and different levels of AP are associated with different intestinal microbiota disorders.²⁰ In mild acute pancreatitis (MAP), Finegoldia exhibited the most significant increase, and Brucella was the species of intestinal microbiota that showed the largest decrease. Moderately severe acute pancreatitis (MSAP) patients had the most significant increase in Anaerococcus and the most significant decrease in Eubacterium hallii. The potential biomarkers of MAP are Finegoldia, E. hallii, and Lachnospiraceae. E. hallii and Anaerococcus are potential diagnostic biomarkers for MSAP (Table 1). According to reports, Firmicutes increase while Bacteroidetes decrease in acute patients’ intestines. Enterococcus in Firmicutes can adhere to host cells, invade them, and traverse the epithelial barrier. This can lead to infection and systemic inflammation. Bacteroidetes are capable of producing SCFAs, which have anti-inflammatory effects and help maintain the integrity of the intestinal barrier, thereby protecting it. Certain pathogenic bacteria within Bacteroidetes, such as E. coli and Shigella, can disrupt the intestinal mucosal barrier, resulting in severe colonic inflammation. Therefore, the imbalance between Firmicutes and Bacteroidetes can aggravate the pathogenetic condition of AP.²⁰ SAP was associated with the most significant increase in the abundance of Enterococcus and the greatest decrease in the abundance of E. hallii.³⁰ The expression of proinflammatory factors such as interleukin (IL)-1, IL-6, and tumor necrosis factor-α (TNF-α) in the serum of SAP patients was positively correlated with the intestinal aerobic bacteria level but negatively correlated with the level of anaerobic bacteria such as Bifidobacterium.⁹ Perhaps modulating the gut flora can reduce the body’s inflammatory response and reduce AP severity.

Table 1.

Effects of alteration of bacteria on AP and GM and their mechanisms.

Grade of AP	Bacteria	Phylum/family	Change in bacteria	Effect on AP	Effect on GM	Mechanism	References
MAP	Faecalibacterium prausnitzii	Firmicutes/Ruminococcaceae	Beneficial and decreased	Aggravation	Negative (migration of intestinal microbiota and overgrowth of intestinal pathogens)	Promote anti-inflammatory properties, such as the production of SCFAs when digesting plant polysaccharides; promotes intestinal epithelial cell proliferation, mucosal repair, and anti-inflammatory responses by inducing IL-10 and regulating T-cell responses in the intestine.	Jandhyala et al.,³¹ Alkanani et al.,³² Wu et al.,³³ Holmes et al.,³⁴ Smith et al.,³⁵ Louis and Flint,³⁶ Rossi et al.,³⁷ Martín et al.³⁸
	Bacteroides	Bacteroidetes/Bacteroidaceae	Harmful and increased	Aggravation; infectious pancreatic necrosis	Negative	Aggravate inflammation by stimulating the intestinal mucosa to produce cytokines and several toxins; possess high numbers of antibiotic resistance genes and are risk factors for autoimmunity. High-protein and high-fat diets increase the abundance of Bacteroides.Cause a thinning of the mucus layer by transforming lactate into SCFAs, which contribute to a decrease in mucin synthesis and destroy the tight junctions, finally leading to increased gut permeability; alter the intestinal barrier function, which results in bacterial overgrowth and impaired immunity.	Hamada et al.,⁵ Wu et al.,³³ Sundin et al.,³⁹ de Goffau et al.,⁴⁰ Smedley et al.,⁴¹ Davis-Richardson et al.,⁴² Mejía-León et al.,⁴³ Brown et al.,⁴⁴ Tlaskalová-Hogenová et al.,⁴⁵ Zhang et al.⁴⁶
	Bacteroides dorei	Bacteroidetes/Bacteroidaceae	Harmful and increased	Aggravation	Negative	Impair the intestinal epithelial layer, manipulate immune system development, and aggravate inflammation.	Davis-Richardson et al.⁴²
	Bacteroides vulgatus	Bacteroidetes/Bacteroidaceae	Harmful and increased	Aggravation	Negative	An opportunistic pathogen causing intraabdominal infections and preventing remission.	Davis-Richardson et al.,⁴² Fujita et al.,⁴⁷ Rath et al.⁴⁸
	Bacteroides fragilis	Bacteroidetes/Bacteroidaceae	Harmful and increased	Aggravation	Negative	Disrupt the tight junctions by proteolytic degradation due to metalloprotease enterotoxins, thus increasing paracellular permeability, with gut inflammation, cell damage, and a loss of microvilli.	Mejía-León et al.,⁴³ Berkes et al.⁴⁹
	Streptococcus	Firmicutes/Streptococcaceae	Harmful and increased	Aggravation	Negative	Correlate with malabsorption or decreased levels of pancreatic enzymes associated with pancreatitis.	Hamada et al.,⁵ Mancabelli et al.⁵⁰
	Saccharopolyspora	Actinobacteria/Pseudonocardiaceae	Harmful and increased	Aggravation	Negative	Enhance inflammatory responses by mediating cytokines and chemokines that recruit inflammatory cells and lead to overproduction of interferon-gamma	Riquelme et al.,⁵¹ Kim et al.⁵²
	Proteobacteria	Proteobacteria	Harmful and increased	Aggravation	Negative	LPS-producing bacteria; increase the abundance of certain pathogens and decrease those of probiotics.Induce a tolerogenic immune program by differentially activating select toll-like receptors in monocytic cells and leading to T-cell anergy.	Zhang et al.,⁴⁶ Ren et al.,⁵³ Pushalkar et al.⁵⁴
	Prevotella	Bacteroidetes/Prevotellaceae	Harmful and increased	Aggravation	Negative	Bacteroides-dominant gut communities and LPS-producing bacteria; carbohydrate-rich diets increase the abundance of Prevotella.Impair the intestinal epithelial barrier function and aggravate inflammation.	Wu et al.,³³ Mejía-León et al.,⁴³ Ren et al.⁵³
	Clostridium lavalense	Firmicutes/Clostridiaceae	Beneficial and decreased	Aggravation	Negative	A butyrate-producing bacterium, maintaining intestinal epithelial barrier function and anti-inflammation; negatively correlates with serum IL-6 levels.	Hamada et al.,⁵ Tan et al.,⁹ Ren et al.,⁵³ Takahashi et al.,⁵⁵ Hague et al.⁵⁶
	Atopobium	Actinobacteria/Coriobacteriaceae	Beneficial and decreased	Aggravation	Negative	Actinobacteria produce many compounds, including antibiotics, anticancer agents, immunosuppressants, anthelmintics, antiviral agents, and extracellular enzymes.	Zhang et al.,⁴⁶ van Bergeijk et al.,⁵⁷ Barka et al.⁵⁸
	Bifidobacterium adolescentis or B. pseudocatenulatum	Actinobacteria/Bifidobacteriaceae	Beneficial and decreased	Aggravation	Negative	Increase the production of butyrate, which is the main energy source for intestinal epithelial cells; exert anti-inflammatory effects and inhibit bacterial translocation.	de Goffau et al.,⁴⁰ Duffy⁵⁹
	Megamonas	Firmicutes	Beneficial and decreased	Aggravation	Negative	The main metabolite is acetic acid, which promotes intestinal peristalsis and relieves constipation.	Mejía-León et al.,⁴³ Tian et al.⁶⁰
	Acidaminococcus intestini	Firmicutes	Harmful and increased	Aggravation	Negative	Positively associated with LPS-stimulated TNF-α production.	Mejía-León et al.,⁴³ Zheng et al.⁶¹
	Finegoldia magna	Firmicutes	Harmful and increased	Aggravation	Negative	An opportunistic pathogen, binding to histones through its surface and the extracellular adhesion protein FAF Finegoldia magna cell wall adhesion protein (FAF) and producing collagenase and gelatinase enzymes to protect bacteria and finally aggravate infection. An anaerobic gram-positive coccus acts as a virulence factor.	Hamada et al.,⁵ Martín et al.,³⁸ Sundin et al.,³⁹ Murphy et al.,⁶² Krepel et al.⁶³
	Blautia	Firmicutes/Lachnospiraceae	Beneficial and decreased	Aggravation	Negative	Reduction in the abundance of Blautia promotes the overgrowth of intestinal bacteria, increases intestinal permeability, and ultimately leads to higher concentrations of endotoxins and the activation of inflammatory cascades.	de Goffau et al.,⁴⁰ Smedley et al.,⁴¹ Davis-Richardson et al.⁴²
	Lachnospira	Firmicutes/Lachnospiraceae	Beneficial and decreased	Aggravation	Negative	Produce butyrate and influence SCFA levels. Produce reuterin, inhibit pathogens, and suppress inflammation in the gut.	Mejía-León et al.⁴³
MSAP	Escherichia–Shigella	Proteobacteria/Enterobacteriaceae	Harmful and increased	Aggravation	Negative	Opportunistic gram-negative bacterial pathogens.Invade the colonic and rectal mucosa, provoking a strong inflammatory response.	Wu et al.,³³ Brown et al.⁴⁴
	Eubacterium hallii	Firmicutes/Lachnospiraceae	Beneficial and decreased	Aggravation	Negative	A butyrate (SCFA)-producing bacterium. Produces reuterin, inhibits pathogens, and suppresses inflammation in the gut.	Zhang et al.,⁴⁶ Fujita et al.⁴⁷
MSAP and SAP	Atopobium	Actinobacteria/Coriobacteriaceae	Beneficial and decreased	Aggravation	Negative	Actinobacteria produce many compounds, including antibiotics, anticancer agents, immunosuppressants, anthelmintics, antiviral agents, and extracellular enzymes.	Zhang et al.,⁴⁶ van Bergeijk et al.,⁵⁷ Barka et al.⁵⁸
	Bacteroides	Bacteroidetes/Bacteroidaceae	Harmful and increased	Aggravation	Negative	Aggravate inflammation by stimulating the intestinal mucosa to produce cytokines and several toxins; possess high numbers of antibiotic resistance genes and are risk factors for autoimmunity. High-protein and high-fat diets increase the abundance of Bacteroides.Cause a thinning of the mucus layer by transforming lactate into SCFAs, which contributes to a decrease in the mucin synthesis, destroys the tight junctions, and finally leads to increased gut permeability; alter the intestinal barrier function, which results in bacterial overgrowth and impaired immunity.	Hamada et al.,⁵ Wu et al.,³³ Sundin et al.,³⁹ de Goffau et al.,⁴⁰ Smedley et al.,⁴¹ Davis-Richardson et al.,⁴² Mejía-León et al.,⁴³ Brown et al.,⁴⁴ Tlaskalová-Hogenová et al.,⁴⁵ Zhang et al.⁴⁶
	Firmicutes	Firmicutes	Beneficial and decreased	Aggravation	Negative	Promote anti-inflammatory properties by producing SCFAs when digesting plant polysaccharides; promote intestinal epithelial cell proliferation, mucosal repair, and anti-inflammatory responses by inducing IL-10 and regulating T-cell responses in the intestine.	Jandhyala et al.,³¹ Alkanani et al.,³² Wu et al.,³³ Holmes et al.,³⁴ Smith et al.,³⁵ Louis and Flint,³⁶ Rossi et al.,³⁷ Martín et al.³⁸
	Proteobacteria	Proteobacteria	Harmful and increased	Aggravation	Negative	LPS-producing bacteria; Increase the abundance of certain pathogens and decrease that of probiotics.Induce a tolerogenic immune program by differentially activating select toll-like receptors in monocytic cells and leading to T-cell anergy.	Zhang et al.,⁴⁶ Ren et al.,⁵³ Pushalkar et al.⁵⁴
	Synergistetes	Synergistetes	Harmful and increased	Aggravation	Negative	Related to LPS biosynthesis, considered a putative periodontal pathogen and is associated with several systemic diseases and inflammatory disorders of the gastrointestinal tract.	Pushalkar et al.,⁵⁴ Hugenholtz et al.,⁶⁴ Amado et al.,⁶⁵ Oliveira et al.,⁶⁶ Deng et al.,⁶⁷ Kumar⁶⁸
	Enterococcus	Firmicutes/Enterococcaceae	Harmful and increased	Aggravation	Negative	Positively correlate with serum IL-6 and endotoxin levels, provoke systemic inflammatory response syndrome and intestinal bacterial translocation.	Tan et al.⁹
	Bifidobacterium	Actinobacteria/Bifidobacteriaceae	Beneficial and decreased	Aggravation	Negative	Negatively correlated with serum IL-6 levels; decrease the population of Bacteroides vulgatus in the gut and ameliorate gut inflammation.	Tan et al.,⁹ Davis-Richardson et al.,⁴² Shiba et al.,⁶⁹ Setoyama et al.⁷⁰
	Lactobacillus	Firmicutes/Lactobacillaceae	Beneficial and decreased	Aggravation	Negative	Cause dysfunction of immune homeostasis in the gut and periphery and hypofunction of microbial anti-infection, accompanied by downmodulation of inflammation by dendritic cells by inducing polarization of regulatory T cells.	Alkanani et al.,³² Bron et al.,⁷¹ Smits et al.,⁷² Penders et al.⁷³
SAP	Staphylococcus	Firmicutes/Staphylococcaceae	Beneficial and decreased	Aggravation	Negative	Promote the growth of anaerobic bacteria, including species of the genera Bifidobacterium, Clostridium, and Bacteroides.	Sahar et al.,¹⁵ Alkanani et al.³²
	Enterococcus	Firmicutes/Enterococcaceae	Harmful and increased	Aggravation	Negative	Positively correlate with serum IL-6 and endotoxin levels, provoke systemic inflammatory response syndrome and intestinal bacterial translocation.	Tan et al.,⁹ Marques et al.⁷⁴

AP, acute pancreatitis; GM, gut microbiota; IL, interleukin; LPS, lipopolysaccharide; MAP, mild acute pancreatitis; MSAP, moderate severe acute pancreatitis; SAP, severe acute pancreatitis; SCFA, short-chain fatty acid; TNF-α, tumor necrosis factor-α.

The influence of AP on intestinal flora changes

Acute pancreatitis-associated gut barrier and functional damage facilitate intestinal flora migration

Intestinal barrier dysfunction was found in both animal models and clinical patients with AP.⁷⁵ The mechanism of intestinal microbiota migration in AP is as follows: intestinal barrier damage and a variety of gastrointestinal polypeptide secretions can destroy Cajal mesenchymal cells,⁷⁶ decrease gastrointestinal movement,⁷⁷ and impair intestinal motility,⁷⁸ resulting in the overgrowth of intestinal bacteria in AP.⁷⁹ Early fasting in patients with AP can cause intestinal ischemia–reperfusion injury, which can lead to intestinal mucosal microcirculation disorders and abnormal release of inflammatory factors and reactive oxygen species (ROS). These substances can cause the oxidative stress response in the intestinal mucosa,⁸⁰ the apoptosis of intestinal epithelial cells, and increased permeability of intestinal capillaries,^81,82 ultimately leading to intestinal barrier function disorders and increased intestinal permeability.^83,84 The intestinal immune barrier function is compromised in patients with AP,⁸⁵ and the level of secretory immunoglobulin A is decreased,⁸⁶ which allows bacteria to pass through the intestinal barrier more easily. In addition to these three effects, long-term fasting and the obstruction of the lower bile duct in patients with SAP can result in a significant decrease in bile secretion or ineffective secretion into the intestine.⁷⁵ Deoxycholic acid in the bile can selectively inhibit gram-positive bacilli (Bacillus, Clostridium, Lactobacillus, and Streptococcus pneumoniae). The reduction in bile secretion impairs the normal balance of the intestinal microbiota, resulting in the activation of an oxidative stress response and intestinal epithelial cell apoptosis, thus increasing bacterial migration.⁸⁷

Effects of secretion of cell damage factors on intestinal flora in AP

Intestinal barrier dysfunction is the most common complication of SAP. Previous clinical studies have shown that elevated serum levels of many inflammatory cytokines in SAP, including TNF-α,⁸⁴ IL-1,⁸⁸ IL-6,⁸⁹ neutrophil elastase (NE), and myeloperoxidase (MPO),⁹⁰ are associated with intestinal barrier dysfunction. One of the main cytokines associated with AP is TNF-α, a proinflammatory cytokine, which is found to have elevated levels both locally, in the intestine, and systemically in patients with intestinal barrier dysfunction.^91,92 An increase in the TNF-α levels can lead to inflammation in the intestinal mucosa and to intestinal epithelial cell apoptosis,^93,94 which can lead to intestinal epithelial mechanical barrier damage and facilitate bacterial displacement.⁹⁵ In addition to direct injury, TNF-α can initiate a positive feedback loop that induces the secretion of other cytokines, such as IL-1 and IL-6, to further injure the intestinal mucosa.⁹⁶ An increase in the IL-1 levels in AP and the risk associated with IL-1 and the IL-1 receptor (IL-1R) in the pathogenesis of pancreatitis have been reported.⁹⁷ IL-1R-deficient mice pretreated with an IL-1R antagonist recombinant human interleukin-1-receptor antagonist (rhIL-1Ra) experience milder pancreatitis after cerulein induction. The activation of IL-1β can also stimulate the local mucosal immune response and cause mucosal injury by stimulating T-cell proliferation and neutrophil entry to the site of injury or infection through the binding of IL-1β and IL-1R.^98,99 Serum IL-6 is another reliable indicator of AP severity that can predict both organ failure and SAP.¹⁰⁰ The production of IL-6 can activate several different pathways in the adaptive immune system, thereby exacerbating inflammation and negatively affecting barrier function.¹⁰¹ Tan et al.⁹ also found that serum IL-6 levels in patients with AP were positively correlated with the abundance of Enterobacter and Enterococcus in the intestinal microbiota and negatively correlated with the abundance of XI groups of Bifidobacterium and Clostridium. In pancreatic tissue from a mouse model of SAP, neutrophil extracellular traps (NETs) decorated with MPO and NE were shown to aggravate tissue damage.¹⁰² Many lethal complications of SAP have been shown to be closely related to NETs. According to previous reports, NETs can disrupt the balance of the intestinal microbiota, cause intestinal epithelial cell damage, and even induce apoptosis, leading to gut barrier damage, increased intestinal mucosal permeability, elevated endotoxin secretion, and imbalances in the GM.^{90,103
–105}

Pancreatic exocrine deficiency affects the composition and diversity of GM in AP

Patients with AP exhibit complications such as pancreatic exocrine impairment (PEI) and acinar cell dysfunction, which significantly impact changes in intestinal microbiota composition,¹⁰⁶ and the secretion of many enzymes, such as lactate and bile acids, declines to a certain level.¹⁰⁷ In animal models of PEI, the intestinal microbes E. coli, Lactobacillus, and Bifidobacterium were increased, and the levels of Fusobacterium and Clostridium hiranonis were decreased, inducing a significant difference in the dysbiosis index between affected animals and healthy individuals.¹⁰⁸ Stool samples from PEI patients were analyzed and showed that pancreatic elastase levels significantly correlated with intestinal flora diversity compared with those of normal individuals, and significant differences were found in the abundances of 22 taxa, such as an increase in Pseudomonas spp. and a decrease in Bacillus spp.¹⁰⁶ These results revealed that changes in pancreatic fluid secretion were also significantly correlated with flora diversity.

Antimicrobial peptide changes in AP-affected intestinal flora

Antimicrobial peptides (AMPs) are oligopeptides that are arranged linearly or circularly and are composed of amino acid residues of different lengths (up to 100). AMPs usually form L-amino acids through secondary structures containing alpha helices, beta sheets, or both.¹⁰⁹ These biomolecules exhibit diverse biological activities against gram-positive and gram-negative bacteria, viruses, fungi, protozoa, and even tumors.¹¹⁰ The Data Repository of AMPs (DRAMP) database includes over 4800 peptides that are antiproteins¹¹¹ and contribute to the maintenance of intestinal bacterial homeostasis and intestinal barrier function.¹¹² AMPs such as the cathelicidin-related AMP (CRAMP) have been reported to be secreted by pancreatic acinar cells, and reduced secretion of pancreatic AMPs can lead to the abnormal growth of intestinal bacteria and the disruption of the intestinal microbiota balance. Moreover, CRAMP deficiency worsens pancreatic inflammation.¹¹³ Decreased expression of ileal terminal AMPs was found in necrotizing pancreatitis.¹¹⁴ Hypertriglyceridemia (HTG) affects the expression of AMPs, including α-defensin, lysozyme, phospholipase A2, and regenerating islet-derived protein 3α (Reg3A),¹¹⁵ in Paneth cells, which may exacerbate HTG-related acute necrotizing pancreatitis in intestinal barrier dysfunction. Pancreatic cells secrete a variety of AMPs to regulate the structure of the intestinal microbiota.¹¹⁶ Lysozyme and α-defensins have activities against gram-negative and gram-positive bacteria, and some experts believe that fecal levels of α-defensins are a surrogate marker for gut microbial homeostasis.^117,118 On the other hand, Reg3A, which has powerful bactericidal activity, can antagonize gram-positive bacteria^119,120 by limiting the number of mucosal-adherent bacteria to separate the GM from the epithelium and reduce bacterial translocation¹²¹ (Table 2).

Table 2.

AMP changes in AP-affected intestinal microbiota.

AMPs	Characteristics	Mechanism	Associated with AP	Associated with GM	References
CRAMP	Reduced	The Orai1 Ca^2⁺ channel, which is needed in pancreatic exocytosis, can suppress the inflammation-associated alteration of intestinal bacteria	Increased mortality in AP	Gastrointestinal inflammation, intestinal bacterial overgrowth or dysbiosis, and systemic infection; impaired immunomodulatory effects	Ahuja et al.,¹⁰ Deng et al.¹¹³
RegIIIγ and β-defensins	Reduced	The GM metabolites SCFAs (including butyrate) activate mTOR in IECs and promote IEC RegIIIγ and β-defensins in a GPR43-dependent manner	Serious pancreatic damage and systemic inflammation	Increased intestinal inflammatory responses; decreased SCFA-induced AMP production	Zhao et al.¹¹⁴
RegIIIγ and β-defensins	Reduced	The GM metabolites SCFAs (including butyrate) activate STAT3 in IECs and promote IEC RegIIIγ and β-defensins in a GPR43-dependent manner	Serious pancreatic damage and systemic inflammation	Inhibition of intestinal immune regulation and intestinal organoid stemness proliferation; decreased AMP secretion	Zhao et al.¹¹⁴
RegIIIγ and RegIIIβ	Reduced	Microbiota can directly affect AMP production by interfering with TLR-TLR ligand interactions	Serious pancreatic damage and systemic inflammation	Decreased AMP secretion	Zhao et al.,¹¹⁴ Menendez et al.,¹²² Brandl et al.,¹²³ Vaishnava et al.¹²⁴
C-type lectins of the RegIII family	Reduced	Bactericidal activity by binding membrane phospholipids and killing bacteria by forming a hexameric membrane-permeabilizing oligomeric pore	Serious pancreatic damage and systemic inflammation (bactericidal for gram-positive but not for gram-negative bacteria)	Antibacterial effects against enteric pathogens; promoting mutualism with the resident microbiota in orthergasia	Wong¹¹², Mukherjee et al.,¹¹⁹ Cash et al.¹²⁰
α-Defensin and lysozyme	Reduced	Intestinal microbiota dysbiosis and decreased levels of AMPs in Paneth cells may participate in the pathogenesis of intestinal barrier dysfunction	Serious pancreatic damage and systemic inflammation	Increased intestinal proinflammatory cytokine (TNF-α, IL-1β, and IL-17A) levels in plasma and tissue; weakened resistance against enteric pathogens; dysbiosis of intestinal microbiota structure and aggravated intestinal barrier dysfunction	Huang et al.,¹¹⁵ Clevers and Bevins,¹¹⁷ Eriguchi et al.,¹¹⁸ Salzman et al.,¹²⁵ Satoh et al.¹²⁶
AMPs secreted by Paneth cells	Reduced	Increase in the concentration of cytosolic Ca²⁺ accompanies granule secretion responding to bacteria or bacterial products, such as lipopolysaccharide	Serious pancreatic damage and systemic inflammation	Dysbiosis of intestinal microbiota and aggravated intestinal barrier dysfunction	Satoh et al.,¹²⁶ Ayabe et al.¹²⁷

AMP, antimicrobial peptide; AP, acute pancreatitis; CRAMP, cathelicidin antimicrobial peptide; GM, gut microbiota; GPR, G protein-coupled receptor; IEC, intestinal epithelial cell; IL, interleukin; MAP, mild acute pancreatitis; MSAP, moderate severe acute pancreatitis; mTOR, mammalian target of rapamycin; Reg, regenerating islet-derived protein; SAP, severe acute pancreatitis; SCFA, short-chain fatty acid; STAT3, signal transducer and activator of transcription 3; TLR, toll-like receptor; TNF-α, tumor necrosis factor-α.

Risk factors that influence the GM and AP

Trillions of microbes live in the gut, and this community plays a vital role in the regulation of both intestinal and pancreatic functions. The underlying common causes of AP, such as biliary obstruction, alcohol misuse, HTG, and a high-fat/sugar diet, may also cause changes in the intestinal flora.¹²⁸ These risk factors affect both AP and the intestinal microflora; thus, interactions between the intestinal microflora and the occurrence of AP can be inferred.

Obesity and hyperlipidemia

Obesity typically presents with low-level systemic inflammation, such as increased leukocyte counts and TNF-α, IL-6, and C-reactive protein levels^129,130; furthermore, it is characterized by increased secretion of biomarkers by adipocytes and is associated with AP. Moreover, macrophages in adipose tissue have been reported to participate in inflammation in obesity via the secretion of proinflammatory cytokines, such as TNF-α and IL-6,¹³¹ both of which have been proven to affect AP and GM.

Obesity can also unmask primary HTG due to genetic causes and is a risk factor for secondary HTG, which is associated with pancreatitis.^132,133 At present, HTG-induced AP (HTG-AP) has become the second leading cause of AP.¹³⁴ Indeed, the proportion of Bacteroides in the intestines of lean mice was found to be higher than that in obese mice after administration of the same diet, while the opposite was true for thick-walled Bacteroides.¹³⁵ Rats fed a high-fat diet showed significant increases in serum low-density lipoprotein, total cholesterol, and triacylglycerol, as well as changes in Bifidobacteria, Lactobacilli, Enterococci, Enterobacteria, and Anaphylactic bacteria in the intestinal flora.¹³⁶ In an animal model of hyperlipidemic necrotizing pancreatitis, researchers also found intestinal microflora imbalances and decreased AMPs in Paneth cells, further confirming that hyperlipidemia can affect the severity of AP and the intestinal microflora.¹¹⁵ Unsaturated fatty acids (UFAs) might be an important factor that can affect both AP and GM in obesity and hyperlipidemia, and these factors are mainly transmitted via the lipolysis of circulating triglycerides.¹³⁷ The insolubility of UFAs in the aqueous environment of the blood can cause microthrombi formation in the pancreatic vasculature, leading to ischemia and pancreatic infarction. As polar molecules, UFAs usually bind with calcium, resulting in their saponification and inactivation in necrotic fat tissue.¹³⁸ Unbound UFAs can increase the serum levels of TNF-α and other inflammatory cytokines,¹³⁹ thereby worsening AP and leading to inflammation of the intestinal mucosa and intestinal epithelial cell apoptosis^93,94 (Figure 1).

Figure 1.

The negative effect of obesity and hypertriglyceridemia both on AP and GM.

In addition to the harmful effects of obesity and hyperlipidemia on the GM, recent studies have shown that the intestinal flora is one of the important environmental factors affecting the occurrence and development of obesity. The intestinal flora can induce adipocytokine gene expression by affecting intestinal epithelial cell fasting, leading to the increased production of triacylglycerols in the body and causing lipid metabolism disorders and the development of obesity.¹⁴⁰ Furthermore, disturbances in the intestinal flora in obese mice may lead to abnormal lipid metabolism, energy metabolism, adipokine synthesis, and cell death, leading to the secretion of a large number of proinflammatory cytokines into the blood and resulting in the exacerbation of pancreatitis.¹¹⁵ Some studies indicated that intake of probiotic preparations could affect serum cholesterol and high-density lipoprotein levels and indirectly lower blood lipids, suggesting that the establishment of normal intestinal flora can help balance lipid metabolism.¹¹³

Alcohol

In recent years, due to changes in diet and increases in alcohol consumption, heavy drinking has become a risk factor for AP, and this condition easily progresses to SAP.¹⁴¹ The toxicity of ethanol is mediated by ethanol itself or its oxidative and nonoxidative metabolism. Oxidative ethanol metabolism potentiates cholecystokinin-induced depolarization by sensitizing pancreatic mitochondria to Ca²⁺-induced mitochondrial permeability transition pore (MPTP) activation, resulting in mitochondrial dysfunction in pancreatic acini and necrosis in the pancreas.¹⁴² Although the main ethanol metabolism in vivo is oxidation, a smaller part undergoes nonoxidative metabolism.^143,144 Incubation of isolated pancreatic acinar cells with fatty acid ethyl esters, one of the nonoxidative ethanol metabolites in vivo, induced mitochondrial depolarization, depletion of cellular adenosine triphosphate,¹⁴⁵ and sustained elevations of intracellular Ca²⁺ levels ultimately associated with cellular dysfunction and cell death.¹⁴⁶ Both alcohol and its metabolites can activate digestive enzymes early in pancreatic acinar tissue, resulting in pancreatic tissue autodigestive injury, and activate pancreatic stellate cells, leading to fibrosis of the pancreas.¹⁴³

On the other hand, alcohol has been shown to have a negative impact on the intestinal flora of healthy people, such as decreasing the biodiversity of the intestinal flora and affecting the overall composition of the microbial community.¹⁴⁵ Disturbances in the intestinal flora may cause disorders of glycolipid energy metabolism and other potential functional pathway changes in the body.¹⁴⁷ Alcohol can lead to changes in the composition of the GIT microbiota and metabolic function, contributing to the well-established association between alcohol-induced oxidative stress and intestinal hyperpermeability to luminal bacterial products.^146
–148 Exposure to ethanol can increase the release of enterogenous gram-negative bacteria-derived lipopolysaccharide (LPS), leading to macrophage activation and the secretion of cytokines, including TNF-α, IL-1β, and IL-6.¹⁴⁹ IL-22 is mainly involved in maintaining the integrity of the epithelial barrier and linking intestinal immune activation with epithelial repair and barrier protection.^150,151 Under inflammatory conditions, IL-22 can be activated through the IL-23-Janus kinase/signal transducer and activator of transcription signaling pathway, resulting in the production of AMPs.¹⁵² Ethanol metabolism in vivo produces acetaldehyde and ROS, which can activate NF-κB and ultimately stimulate the immune response,¹⁵³ decrease intestinal expression of IL-22, and alter gut epithelial integrity, causing an increase in intestinal permeability and bacterial translocation¹⁵⁴ (Figure 2).

Figure 2.

The mechanism and negative effect of ethanol metabolism on AP and GM.

High glucose and insulin resistance

Pancreatic damage, pancreatitis, imbalances in the GM, and blood sugar imbalances may be interrelated.¹⁴⁸ AP exhibits hyperglycemia in the early stage,¹⁵⁵ which can persist as secondary diabetes even after pancreatitis has been resolved.¹⁵⁶ Chronic hyperglycemia may cause oxidative stress, mitochondrial damage, the production of advanced glycation end products (AGEs), and the expression of the receptor for AGEs (RAGE), leading to tissue injury.¹⁵⁷

Researchers have shown that hyperglycemia enhances mitochondrial oxidative stress by increasing ROS production, which is a key step in the pathogenesis of AP,¹⁵⁸ and mediates lipid peroxidation by increasing cytosolic Ca²⁺.^159,160 Furthermore, increased intracellular Ca²⁺ is also required for premature protease activation, which is an early step in the induction of AP.¹⁵⁸ Elevated glucose levels begin to form covalent conjugates with plasma proteins through a nonenzymatic process called AGE formation.¹⁶¹ In combination with AGEs, RAGE promotes the development of pancreatitis in part by mediating uninduced nucleosome activation and proinflammatory mediator release via the absence in melanoma 2 (AIM2) inflammasome activation and proinflammatory mediator release in macrophages in an animal model of AP.¹⁶² Under glycoxidative stress, stimulated macrophages can induce oxidative stress and NF-κB activation through activation of the PR21ras and MAPK signaling pathways.¹⁶³ Active NF-κB induces the production of TNF-α, which, in turn, leads to enhanced ROS production and more severe damage to tissues.¹⁶⁴ In addition, hyperglycemia was shown to compromise the integrity of the intestinal barrier through glucose transporter 2 (GLUT2)-dependent reprograming of the intestinal epithelial cell transcriptome and disruption of tight and adherence junctions, leading to intestinal flora disorders.^165,166 The GM composition of patients and animals with elevated blood glucose was also significantly different from that of normal controls.^167,168

Insulin resistance, which is a kind of metabolic dysfunction associated with type 2 diabetes mellitus, is another critical factor that affects both AP and the GM.¹⁶⁹ Observational studies have shown an increased risk of AP among people with diseases linked to insulin resistance.^170
–172 Various factors and hormones, such as NF-κB, TNF-α, amylin, leptin, and IL-6, have recently been shown to be increased in patients with insulin resistance, and those factors have been demonstrated to cause AP and intestinal flora disorders.^173
–177 In addition, insulin resistance often causes hyperinsulinemia, which can inhibit mucus secretion by promoting fatty acid synthase, to break the integrity of the intestinal barrier, leading to GMs.^165,178 Furthermore, insulin resistance has been regarded as a novel risk factor for post-endoscopic retrograde cholangiopancreatography pancreatitis¹⁷⁹ and an independent prognostic factor in patients with AP.¹⁸⁰

Intestinal microbes can also increase insulin resistance by influencing host energy metabolism and the integrity of the intestinal barrier; thus, inflammatory mediators can be transmitted into circulation.¹⁸¹

Curative substances influence both AP and GM

AP often leads to flora disorder, but some protective cytokines play key roles; for example, IL-22 and IL-23 attenuate intestinal flora disorders.^152,182,183 Propolis has recently been reported to reduce the serum levels of proinflammatory cytokines (TNF-α, IL-1β, and IL-6) and increase IL-22 levels, thereby reducing pancreatic neutrophil infiltration and maintaining the intestinal flora in AP rats.¹⁸⁴ Store-operated calcium entry (SOCE) modulators,¹⁸⁵ such as Pyrtriazoles, and the Orai Ca²⁺ channel inhibitor CM4620, which can reduce endoplasmic reticulum calcium influx, target both parenchymal and immune cells to reduce inflammation in experimental AP.¹⁸⁶ By inhibiting immune cells, SOCE inhibitors can treat imbalances in the GM. Okra pectin could relieve the inflammatory response by inhibiting the expression of proinflammatory mediators, preventing intestinal barrier injury, and regulating the intestinal microbiota by upregulating AMPs and occludin in an AP model.¹⁸⁷ Probiotics have been reported to significantly attenuate pathological injury of the pancreas and reduce the incidence of complications, such as infection, in patients with AP.¹⁸⁸ However, the elevated levels of lactic acid produced by bacterial overgrowth in the small bowel and fermentation of carbohydrates significantly contributed to the high death rate. When considering substituting supplementation for individuals with AP, it is necessary to assess the time, type, appropriate, effective doses of probiotics, and prevent bacterial overgrowth.^20,189,190 Some traditional Chinese medicine (TCM) treatments also have effects on both AP and the GM. Saponin A, a monomer of total saikosaponins extracted from Bupleuri Radix, has strong antioxidant properties and can affect the composition of GM by increasing the relative abundance of Lactobacillus and Prevotella species to decrease the development of SAP in rat models.¹⁹¹ Picroside II is one of the main effective components extracted from Picrorhiza scrophulariiflora Pennell that can improve the intestinal microbiota by inactivating oxidant and inflammatory signals to improve intestinal barrier injury in an SAP rat model.²⁸ Some studies have reported that berberine can not only repair the gut barrier structure to decrease GM diversity but also reduce blood glucose levels and attenuate insulin resistance; moreover, berberine is regarded as a potential therapeutic agent for AP.^192
–194 Meng et al. used acupuncture and moxibustion to stimulate ST36 points to treat SAP based on conventional treatments and found that adjuvant acupuncture treatment could reduce the permeability of intestinal mucosa capillaries, alleviate intestinal dysfunction, and promote recovery in patients¹⁹⁵ (Tables 3 and 4).

Table 3.

Curative substances influencing both AP and GM.

Substance	Effect on AP	Effect on GM	Mechanism	References
IL-22	Relieves inflammation and tissue injury	Promotes epithelial repair and barrier protection	Activation of inflammation, mediated through the JAK/STAT signaling pathway, results in the production of AMPs, finally repairing barrier damage or controlling pathogenic bacterial expansion	Sonnenberg et al.,^150,151 Li et al.,¹⁵² Zheng et al.,¹⁹⁶ Zindl et al.¹⁹⁷
IL-23	Relieves inflammation and tissue injury	Promotes epithelial repair and barrier protection	Promotes IL-22 production	Ngo et al.,¹⁸² Shih et al.¹⁸³
Propolis	Reduces neutrophil infiltration in the pancreas	Reduces intestinal inflammation	Reduces the serum levels of proinflammatory cytokines (TNF-α, IL-1β, and IL-6) and increases that of IL-22	Al-Hariri et al.¹⁸⁴
SOCE modulators
Pyrtriazole	Reduce inflammation in the pancreas	Treat an imbalance of the GM	Reduce calcium influx in the endoplasmic reticulum	Riva et al.,¹⁸⁵ Waldron et al.¹⁸⁶
CM4620	Reduce inflammation in the pancreas	Treat an imbalance of the GM	Reduce calcium influx in the endoplasmic reticulum	Riva et al.,¹⁸⁵ Waldron et al.¹⁸⁶
Okra pectin	Reduces inflammation in the pancreas	Prevents intestinal barrier inflammatory injury and regulates intestinal microbiota	Relieves inflammatory responses and intestinal barrier injury and regulates intestinal microbiota by inhibiting the expression of proinflammatory mediators or upregulating AMPs and occludin	Xiong et al.¹⁸⁷
Choline	Choline deficiency is related to exocrine pancreatic insufficiency	Choline deficiency is associated with bacterial overgrowth in the small intestine	Choline is a tightly regulated tissue component in the form of phosphatidylcholine and sphingomyelin in all membranes and many secretions	Bernhard¹⁹⁸

AMP, antimicrobial peptide; AP, acute pancreatitis; GM, gut microbiota; IL, interleukin; SOCE, store-operated calcium entry; JAK, Janus kinase; STAT, signal transducer and activator of transcription; TNF-α, tumor necrosis factor-α.

Table 4.

Promising prebiotic agent for the treatment of SAP.

Substance	Effect on AP	Effect on GM	Mechanism	References
SCFAs	Anti-inflammatory effects on protecting against severe AP-associated lung injury	Protecting intestinal barrier, decreasing bacterial translocation	SCFAs produced by gut microbiome and has a protective effect against pathogen proliferation, inflammatory response, and intestinal barrier injury	van den Berg et al.,²¹ Jia et al.,²⁴ Pan et al.,²⁹ Patel et al.,¹⁹⁰ Wang et al.,^199,200 Zhang et al.²⁰¹
Six different strains of probiotic prophylaxis mixture	More multiorgan failure-related deaths	More bowel ischemia	Combination of probiotics had no beneficial effect on the occurrence of infectious complications and been damaged to bowel wall because of inflammatory injury and enteral feeding aggravating intestinal mucosal ischemia	Bongaerts and Severijnen,¹⁸⁹ Besselink et al.,²⁰² Rahman et al.,²⁰³ Besselink et al.²⁰⁴
Glutathione biosynthesis by multispecies probiotics	Reducing pancreatic oxidative stress	Reducing oxidative stress in the ileum	This probiotics mixture increases the biosynthesis of glutathione and reduces oxidative stress both in pancreas and ileum	Lutgendorff et al.,^205,206
Probiotics capsules (such as a mixture of Bacillus subtilis and Enterococcus faecium)	Reducing pancreatic injury	Reducing bacterial translocation and increasing food tolerance	Gut microbiome plays important role in the pathogenesis of AP. Probiotics improve intestinal microecology and food tolerance, decrease the inflammation	Hooijmans et al.,¹⁸⁸ Zhu et al.,²⁰⁷ Tian et al.²⁰⁸
Chitosan oligosaccharides (COS)	COS decrease inflammatory infiltration and oxidative stress	Remodeling gut dysbiosis by increasing probiotics Akkermansia and eliminating pathogenic bacteria Escherichia–Shigella and Enterococcus	Lighting oxidative stress, reducing proinflammatory cytokine, and balancing intestinal homeostasis	Mei et al.²⁰⁹
Bifidobacterium spp. (B. animalis) metabolite lactate	Reducing pancreatic and systemic inflammation	B. animalis metabolite lactate is the energy source for intestinal epithelial cells and inhibits bacterial translocation	B. animalis colonization and B. animalis metabolite lactate administration could relieve macrophage-associated local and systemic inflammation through its metabolite lactate-related TLR4/MyD88- and NLRP3/Caspase1-dependent pathway	Li et al.²¹⁰

AP, acute pancreatitis; COS, chitosan oligosaccharides; SCFA, short-chain fatty acid; TLR, toll-like receptor.

Future research prospects

SAP is a severe inflammatory disease of the pancreas and results in a high mortality rate when accompanied by multiple organ dysfunction or secondary infection.²¹¹ Studies have shown that most pancreatic and extra-pancreatic organ infections originate in the intestine and induce inflammatory responses, which are major causes of ‘secondary attack’ and increased late death of patients with SAP.²¹² Changes in the GM play an important role in intestinal homeostasis and aggravate the inflammatory response under intestinal flora dysfunction in AP.^4,5 The migration and proportion of intestinal flora influence the development and severity of AP. However, the molecular mechanism and signaling pathways associated with changes in the intestinal flora in AP are still unclear.²¹³ The dominant intestinal microbiota species in MAP, MSAP, and SAP were Bacteroides, Escherichia–Shigella, and Enterococcus, respectively.²⁰ A majority of diseases are accompanied by changes in the microbiota, and whether there is a way to detect GM species could be helpful in predicting or diagnosing SAP.²¹⁴

Obesity and hyperlipidemia are regarded as chronic and systemic inflammatory states induced by adipocytes, which secrete a variety of proinflammatory cytokines and act as reservoirs of inflammatory factors.²³ When obesity and hyperlipidemia cause AP and an intestinal microbiota imbalance,¹¹⁵ the intestinal microbiota also causes disordered lipid metabolism and the development of obesity by mediating adipocytokine gene expression, leading to a vicious cycle.¹⁴⁰ Pancreatic endocrine cells participate in the regulation of blood glucose metabolism. Hyperglycemia exacerbates mitochondrial oxidative stress, increases intracellular Ca²⁺ levels, and ultimately promotes the progression of AP.^158,160 Patients with AP generally have insulin resistance,^80,83,86 and gut microbes have been reported to increase insulin resistance.¹⁸¹ Insulin resistance also causes AP and intestinal microbiota disorders.^85,215,216 Glucose and lipids are sources of energy metabolism and are also factors associated with metabolic diseases. The specific GM species in AP combined with the metabolic disorders associated with glucose and lipids need further study. The effect of probiotics on the treatment of AP combined with metabolic disorders associated with glucose and lipids might be worth studying.^31,161

There is currently no specific treatment for AP. The intestinal flora attenuates the severity of AP, and personalized probiotic intervention is considered a future trend.²¹⁷ The timepoint, dose, and effectiveness of probiotics used for the treatment of AP are worthwhile of further experiments and clinical studies. In addition, the safety issue of probiotic therapy cannot be ignored.²¹⁸ TCM, with multiple approaches including decoctions, powders, acupuncture, and moxibustion, has been reported to improve inflammatory or metabolic disorders.^219
–222 Whether treatments combining probiotics and TCM could be beneficial for SAP patients or whether the curative factors mentioned above may be used to prevent pancreatitis are unclear, and few studies have focused on this issue.

In conclusion, the interaction between the GM and inflammatory responses provides a new understanding of AP disease progression and treatment. Further studies on the interaction of GM and inflammatory responses in AP are needed.

Footnotes

Acknowledgements

The authors thank Hui-Juan Chen at Chengdu Qiantu Culture Communication Co., Ltd., for preparing the figures included in this paper.

Declarations

References

Tao

Zhao

, et al. LncRNA-PVT1 aggravates severe acute pancreatitis by promoting autophagy via the miR-30a-5p/Beclin-1 axis. Am J Transl Res 2020; 12: 5551–5562.

Hollemans

Hallensleben

NDL

Mager

, et al. Pancreatic exocrine insufficiency following acute pancreatitis: systematic review and study level meta-analysis. Pancreatology 2018; 18: 253–262.

Quigley

. Gut bacteria in health and disease. Gastroenterol Hepatol 2013; 9: 560–569.

Biedermann

Rogler

. The intestinal microbiota: its role in health and disease. Eur J Pediatr 2015; 174: 151–167.

Hamada

Masamune

Nabeshima

, et al. Differences in gut microbiota profiles between autoimmune pancreatitis and chronic pancreatitis. Tohoku J Exp Med 2018; 244: 113–117.

Lerch

Gorelick

. Models of acute and chronic pancreatitis. Gastroenterology 2013; 144: 1180–1193.

Andersson

Wang

. Gut barrier dysfunction in experimental acute pancreatitis. Ann Acad Med Singap 1999; 28: 141–146.

Frossard

Steer

Pastor

. Acute pancreatitis. Lancet 2008; 371: 143–152.

Tan

Ling

Huang

, et al. Dysbiosis of intestinal Microbiota associated with inflammation involved in the progression of acute pancreatitis. Pancreas 2015; 44: 868–875.

10.

Ahuja

Schwartz

Tandon

, et al. Orai1-mediated antimicrobial secretion from pancreatic acini shapes the gut microbiome and regulates gut innate immunity. Cell Metab 2017; 25: 635–646.

11.

Wang

Tang

, et al. Bacteremia in patients with acute pancreatitis as revealed by 16S ribosomal RNA gene-based techniques. Crit Care Med 2013; 41: 1938–1950.

12.

Watanabe

Sadakane

Yagama

, et al. Nucleotide-binding oligomerization domain 1 acts in concert with the cholecystokinin receptor agonist, cerulein, to induce IL-33-dependent chronic pancreatitis. Mucosal Immunol 2016; 9: 1234–1249.

13.

Tsuji

Watanabe

Kudo

, et al. Sensing of commensal organisms by the intracellular sensor NOD1 mediates experimental pancreatitis. Immunity 2012; 37: 326–338.

14.

Watanabe

Kudo

Strober

. Immunopathogenesis of pancreatitis. Mucosal Immunol 2017; 10: 283–298.

15.

Sahar

Kozarek

Kanji

, et al. The microbiology of infected pancreatic necrosis in the era of minimally invasive therapy. Eur J Clin Microbiol Infect Dis 2018; 37: 1353–1359.

16.

Mourad

Evans

Kalidindi

, et al. Prophylactic antibiotics in acute pancreatitis: endless debate. Ann R Coll Surg Engl 2017; 99: 107–112.

17.

Reuken

Albig

Rödel

, et al. Fungal infections in patients with infected pancreatic necrosis and pseudocysts: risk factors and outcome. Pancreas 2018; 47: 92–98.

18.

Akshintala

Talukdar

Singh

, et al. The gut microbiome in pancreatic disease. Clin Gastroenterol Hepatol 2019; 17: 290–295.

19.

Zhu

, et al. Gut microbiota dysbiosis worsens the severity of acute pancreatitis in patients and mice. J Gastroenterol 2019; 54: 347–358.

20.

Xiong

, et al. Identification of dysfunctional gut Microbiota through rectal swab in patients with different severity of acute pancreatitis. Dig Dis Sci 2020; 65: 3223–3237.

21.

van den Berg

van Dalen

Hyoju

, et al. Western-type diet influences mortality from necrotising pancreatitis and demonstrates a central role for butyrate. Gut 2021; 70: 915–927.

22.

Deng

W-S

Zhang

, et al. Arpin contributes to bacterial translocation and development of severe acute pancreatitis. World J Gastroenterol 2015; 21: 4293–4301.

23.

, et al. The interplay between the gut microbiota and NLRP3 activation affects the severity of acute pancreatitis in mice. Gut Microbes 2020; 11: 1774–1789.

24.

Jia

Chen

Yang

, et al. Combinatory antibiotic treatment protects against experimental acute pancreatitis by suppressing gut bacterial translocation to pancreas and inhibiting NLRP3 inflammasome pathway. Innate Immun 2020; 26: 48–61.

25.

Pan

Niu

Fang

, et al. Clostridium butyricum strains suppress experimental acute pancreatitis by maintaining intestinal homeostasis. Mol Nutr Food Res 2019; 63: e1801419.

26.

Zheng

Lou

Fan

, et al. Commensal Escherichia coli aggravates acute necrotizing pancreatitis through targeting of intestinal epithelial cells. Appl Environ Microbiol 2019; 85: e00059-19.

27.

Wan

Zhu

Bian

, et al. Improvement of gut microbiota by inhibition of P38 mitogen-activated protein kinase (MAPK) signaling pathway in rats with severe acute pancreatitis. Med Sci Monit 2019; 25: 4609–4616.

28.

Piao

Liu

Sui

, et al. Picroside II improves severe acute pancreatitis-induced intestinal barrier injury by inactivating oxidative and inflammatory TLR4-dependent PI3K/AKT/NF-κB signaling and improving gut microbiota. Oxid Med Cell Longev 2020; 2020: 3589497.

29.

Pan

Fang

Wang

, et al. Butyrate ameliorates caerulein-induced acute pancreatitis and associated intestinal injury by tissue-specific mechanisms. Br J Pharmacol 2019; 176: 4446–4461.

30.

Wan

Zhu

Pan

, et al. Bile acid supplementation improves murine pancreatitis in association with the gut microbiota. Front Physiol 2020; 11: 650.

31.

Jandhyala

Madhulika

Deepika

, et al. Altered intestinal microbiota in patients with chronic pancreatitis: implications in diabetes and metabolic abnormalities. Sci Rep 2017; 7: 43640.

32.

Alkanani

Hara

Gottlieb

, et al. Alterations in intestinal microbiota correlate with susceptibility to type 1 diabetes. Diabetes 2015; 64: 3510–3520.

33.

Chen

Hoffmann

, et al. Linking long-term dietary patterns with gut microbial enterotypes. Science 2011; 334: 105–108.

34.

Holmes

Marchesi

, et al. Gut microbiota composition and activity in relation to host metabolic phenotype and disease risk. Cell Metab 2012; 16: 559–564.

35.

Smith

Howitt

Panikov

, et al. The microbial metabolites, short-chain fatty acids, regulate colonic Treg cell homeostasis. Science 2013; 341: 569–573.

36.

Louis

Flint

. Diversity, metabolism and microbial ecology of butyrate-producing bacteria from the human large intestine. FEMS Microbiol Lett 2009; 294: 1–8.

37.

Rossi

van Berkel

Chain

, et al. Faecalibacterium prausnitzii A2-165 has a high capacity to induce IL-10 in human and murine dendritic cells and modulates T cell responses. Sci Rep 2016; 6: 18507.

38.

Martín

Miquel

Chain

, et al. Faecalibacterium prausnitzii prevents physiological damages in a chronic low-grade inflammation murine model. BMC Microbiol 2015; 15: 67.

39.

Sundin

Rangel

Repsilber

, et al. Cytokine response after stimulation with key commensal bacteria differ in post-infectious irritable bowel syndrome (PI-IBS) patients compared to healthy controls. PLoS One 2015; 10: e0134836.

40.

de Goffau

Luopajärvi

Knip

, et al. Fecal microbiota composition differs between children with β-cell autoimmunity and those without. Diabetes 2013; 62: 1238–1244.

41.

Smedley

3rd Fisher

Sayeed

, et al. The enteric toxins of Clostridium perfringens. Rev Physiol Biochem Pharmacol 2004; 152: 183–204.

42.

Davis-Richardson

Ardissone

Dias

, et al. Bacteroides dorei dominates gut microbiome prior to autoimmunity in Finnish children at high risk for type 1 diabetes. Front Microbiol 2014; 5: 678.

43.

Mejía-León

Petrosino

Ajami

, et al. Fecal microbiota imbalance in Mexican children with type 1 diabetes. Sci Rep 2014; 4: 3814.

44.

Brown

Davis-Richardson

Giongo

, et al. Gut microbiome metagenomics analysis suggests a functional model for the development of autoimmunity for type 1 diabetes. PLoS One 2011; 6: e25792.

45.

Tlaskalová-Hogenová

Šteˇpánková

Kozáková

, et al. The role of gut microbiota (commensal bacteria) and the mucosal barrier in the pathogenesis of inflammatory and autoimmune diseases and cancer: contribution of germ-free and gnotobiotic animal models of human diseases. Cell Mol Immunol 2011; 8: 110–120.

46.

Zhang

, et al. Intestinal microbial community differs between acute pancreatitis patients and healthy volunteers. Biomed Environ Sci 2018; 31: 81–86.

47.

Fujita

Eishi

Ishige

, et al. Quantitative analysis of bacterial DNA from Mycobacteria spp., Bacteroides vulgatus, and Escherichia coli in tissue samples from patients with inflammatory bowel diseases. J Gastroenterol 2002; 37: 509–516.

48.

Rath

Wilson

Sartor

. Differential induction of colitis and gastritis in HLA-B27 transgenic rats selectively colonized with Bacteroides vulgatus or Escherichia coli. Infect Immun 1999; 67: 2969–2974.

49.

Berkes

Viswanathan

Savkovic

, et al. Intestinal epithelial responses to enteric pathogens: effects on the tight junction barrier, ion transport, and inflammation. Gut 2003; 52: 439–451.

50.

Mancabelli

Milani

Lugli

, et al. Identification of universal gut microbial biomarkers of common human intestinal diseases by meta-analysis. FEMS Microbiol Ecol 2017; 93: fix153.

51.

Riquelme

Zhang

, et al. Tumor microbiome diversity and composition influence pancreatic cancer outcomes. Cell 2019; 178: 795–806.e12.

52.

Kim

Park

Brand

, et al. Protein kinase D1 is essential for the proinflammatory response induced by hypersensitivity pneumonitis-causing thermophilic actinomycetes Saccharopolyspora rectivirgula. J Immunol 2010; 184: 3145–3156.

53.

Ren

Jiang

Xie

, et al. Gut microbial profile analysis by MiSeq sequencing of pancreatic carcinoma patients in China. Oncotarget 2017; 8: 95176–95191.

54.

Pushalkar

Hundeyin

Daley

, et al. The pancreatic cancer microbiome promotes oncogenesis by induction of innate and adaptive immune suppression. Cancer Discov 2018; 8: 403–416.

55.

Takahashi

Nishida

Fujimoto

, et al. Reduced abundance of butyrate-producing bacteria species in the fecal microbial community in Crohn’s disease. Digestion 2016; 93: 59–65.

56.

Hague

Butt

Paraskeva

. The role of butyrate in human colonic epithelial cells: an energy source or inducer of differentiation and apoptosis? Proc Nutr Soc 1996; 55: 937–943.

57.

van Bergeijk

Terlouw

Medema

, et al. Ecology and genomics of actinobacteria: new concepts for natural product discovery. Nat Rev Microbiol 2020; 18: 546–558.

58.

Barka

Vatsa

Sanchez

. Taxonomy, physiology, and natural products of actinobacteria. Microbiol Mol Biol Rev 2016; 80: 1–43.

59.

Duffy

. Interactions mediating bacterial translocation in the immature intestine. J Nutr 2000; 130: 432s–436s.

60.

Tian

Zuo

Guo

, et al. Potential role of fecal microbiota in patients with constipation. Therap Adv Gastroenterol 2020; 13: 1756284820968423.

61.

Zheng

Hoffman

Chen

, et al. Dietary inflammatory potential in relation to the gut microbiome: results from a cross-sectional study. Br J Nutr 2020; 124: 931–942.

62.

Murphy

Mohanty

Frick

. FAF and SufA: proteins of Finegoldia magna that modulate the antibacterial activity of histones. J Innate Immun 2014; 6: 394–404.

63.

Krepel

Gohr

Walker

, et al. Enzymatically active Peptostreptococcus magnus: association with site of infection. J Clin Microbiol 1992; 30: 2330–2334.

64.

Hugenholtz

Hooper

Kyrpides

. Focus: Synergistetes. Environ Microbiol 2009; 11: 1327–1329.

65.

Amado

PPP

Kawamoto

Albuquerque-Souza

, et al. Oral and fecal microbiome in molar-incisor pattern periodontitis. Front Cell Infect Microbiol 2020; 10: 583761.

66.

Oliveira

Fermiano

Feres

, et al. Levels of candidate periodontal pathogens in subgingival biofilm. J Dent Res 2016; 95: 711–718.

67.

Deng

Szafrański

Jarek

, et al. Dysbiosis in chronic periodontitis: key microbial players and interactions with the human host. Sci Rep 2017; 7: 3703.

68.

Kumar

. From focal sepsis to periodontal medicine: a century of exploring the role of the oral microbiome in systemic disease. J Physiol 2017; 595: 465–476.

69.

Shiba

Aiba

Ishikawa

, et al. The suppressive effect of bifidobacteria on Bacteroides vulgatus, a putative pathogenic microbe in inflammatory bowel disease. Microbiol Immunol 2003; 47: 371–378.

70.

Setoyama

Imaoka

Ishikawa

, et al. Prevention of gut inflammation by Bifidobacterium in dextran sulfate-treated gnotobiotic mice associated with Bacteroides strains isolated from ulcerative colitis patients. Microbes Infect 2003; 5: 115–122.

71.

Bron

van Baarlen

Kleerebezem

. Emerging molecular insights into the interaction between probiotics and the host intestinal mucosa. Nat Rev Microbiol 2011; 10: 66–78.

72.

Smits

Engering

van der Kleij

, et al. Selective probiotic bacteria induce IL-10-producing regulatory T cells in vitro by modulating dendritic cell function through dendritic cell-specific intercellular adhesion molecule 3-grabbing nonintegrin. J Allergy Clin Immunol 2005; 115: 1260–1267.

73.

Penders

Thijs

Vink

, et al. Factors influencing the composition of the intestinal microbiota in early infancy. Pediatrics 2006; 118: 511–521.

74.

Marques

Wall

Ross

, et al. Programming infant gut microbiota: influence of dietary and environmental factors. Curr Opin Biotechnol 2010; 21: 149–156.

75.

Liu

Huang

Luo

, et al. Bacterial translocation in acute pancreatitis. Crit Rev Microbiol 2019; 45: 539–547.

76.

Zhou

Gao

, et al. Octreotide ameliorates intestinal dysmotility by interstitial cells of Cajal protection in a rat acute necrotizing pancreatitis model. Pancreas 2011; 40: 1226–1233.

77.

Zhou

Gao

Zou

, et al. Effect of octreotide on enteric motor neurons in experimental acute necrotizing pancreatitis. PLoS One 2012; 7: e52163.

78.

Leveau

Wang

Soltesz

, et al. Alterations in intestinal motility and microflora in experimental acute pancreatitis. Int J Pancreatol 1996; 20: 119–125.

79.

Van Felius

Akkermans

Bosscha

, et al. Interdigestive small bowel motility and duodenal bacterial overgrowth in experimental acute pancreatitis. Neurogastroenterol Motil 2003; 15: 267–276.

80.

Tian

Tan

Wang

, et al. The role of intestinal mucosa oxidative stress in gut barrier dysfunction of severe acute pancreatitis. Eur Rev Med Pharmacol Sci 2013; 17: 349–355.

81.

Andersson

Wang

Ihse

. The influence of abdominal sepsis on acute pancreatitis in rats: a study on mortality, permeability, arterial pressure, and intestinal blood flow. Pancreas 1995; 11: 365–373.

82.

Wen

Zheng

Jiang

, et al. Effect of intestinal epithelial autophagy on bacterial translocation in severe acute pancreatitis. Clin Res Hepatol Gastroenterol 2017; 41: 703–710.

83.

Wang

, et al. Dynamic alteration of the colonic microbiota in intestinal ischemia-reperfusion injury. PLoS One 2012; 7: e42027.

84.

Brivet

Emilie

Galanaud

. Pro- and anti-inflammatory cytokines during acute severe pancreatitis: an early and sustained response, although unpredictable of death. Parisian Study Group on Acute Pancreatitis. Crit Care Med 1999; 27: 749–755.

85.

Braganza

. Mast cell control: likely modus operandi of panhaematin in experimental pancreatitis. Gut 2012; 61: 632.

86.

Zhong

Cai

, et al. Protective effect of galactooligosaccharide-supplemented enteral nutrition on intestinal barrier function in rats with severe acute pancreatitis. Clin Nutr 2009; 28: 575–580.

87.

Reinehr

Becker

Keitel

, et al. Bile salt-induced apoptosis involves NADPH oxidase isoform activation. Gastroenterology 2005; 129: 2009–2031.

88.

Manohar

Verma

Venkateshaiah

, et al. Pathogenic mechanisms of pancreatitis. World J Gastrointest Pharmacol Ther 2017; 8: 10–25.

89.

Aoun

Chen

Reighard

, et al. Diagnostic accuracy of interleukin-6 and interleukin-8 in predicting severe acute pancreatitis: a meta-analysis. Pancreatology 2009; 9: 777–785.

90.

Kang

Chen

, et al. Targeting neutrophil extracellular traps in severe acute pancreatitis treatment. Therap Adv Gastroenterol 2020; 13: 1756284820974913.

91.

Horiuchi

Mitoma

Harashima

, et al. Transmembrane TNF-alpha: structure, function and interaction with anti-TNF agents. Rheumatology 2010; 49: 1215–1228.

92.

Reimund

Wittersheim

Dumont

, et al. Increased production of tumour necrosis factor-alpha interleukin-1 beta, and interleukin-6 by morphologically normal intestinal biopsies from patients with Crohn's disease. Gut 1996; 39: 684–689.

93.

Zeissig

Bürgel

Günzel

, et al. Changes in expression and distribution of claudin 2, 5 and 8 lead to discontinuous tight junctions and barrier dysfunction in active Crohn’s disease. Gut 2007; 56: 61–72.

94.

Garcia-Carbonell

Wong

Kim

, et al. Elevated A20 promotes TNF-induced and RIPK1-dependent intestinal epithelial cell death. Proc Natl Acad Sci U S A 2018; 115: E9192–e9200.

95.

Clark

Patel

Chadwick

, et al. Glutamine deprivation facilitates tumour necrosis factor induced bacterial translocation in Caco-2 cells by depletion of enterocyte fuel substrate. Gut 2003; 52: 224–230.

96.

Hunter

Jones

. IL-6 as a keystone cytokine in health and disease. Nat Immunol 2015; 16: 448–457.

97.

Tanaka

Murata

Uda

, et al. Interleukin-1 receptor antagonist modifies the changes in vital organs induced by acute necrotizing pancreatitis in a rat experimental model. Crit Care Med 1995; 23: 901–908.

98.

Man

Kanneganti

. Regulation of inflammasome activation. Immunol Rev 2015; 265: 6–21.

99.

Sahoo

Ceballos-Olvera

del Barrio

, et al. Role of the inflammasome, IL-1β, and IL-18 in bacterial infections. ScientificWorldJournal 2011; 11: 2037–2050.

100.

Sathyanarayan

Garg

Prasad

, et al. Elevated level of interleukin-6 predicts organ failure and severe disease in patients with acute pancreatitis. J Gastroenterol Hepatol 2007; 22: 550–554.

101.

Schoultz

Keita

ÅV

. Cellular and molecular therapeutic targets in inflammatory bowel disease-focusing on intestinal barrier function. Cells 2019; 8: 193.

102.

Merza

Hartman

Rahman

, et al. Neutrophil extracellular traps induce trypsin activation, inflammation, and tissue damage in mice with severe acute pancreatitis. Gastroenterology 2015; 149: 1920–1931.e8.

103.

Gao

Hao

Yan

, et al. Neutrophil extracellular traps contribute to the intestine damage in endotoxemic rats. J Surg Res 2015; 195: 211–218.

104.

Liang

Wang

, et al. Ameliorating gut microenvironment through staphylococcal nuclease-mediated intestinal NETs degradation for prevention of type 1 diabetes in NOD mice. Life Sci 2019; 221: 301–310.

105.

Marin-Esteban

Turbica

Dufour

, et al. Afa/Dr diffusely adhering Escherichia coli strain C1845 induces neutrophil extracellular traps that kill bacteria and damage human enterocyte-like cells. Infect Immun 2012; 80: 1891–1899.

106.

Frost

Kacprowski

Rühlemann

, et al. Impaired exocrine pancreatic function associates with changes in intestinal microbiota composition and diversity. Gastroenterology 2019; 156: 1010–1015.

107.

Paragomi

Phillips

Machicado

, et al. Post-acute pancreatitis pancreatic exocrine insufficiency: rationale and methodology of a prospective, observational, multicenter cohort study. Pancreas 2021; 50: 147–152.

108.

Blake

Guard

Honneffer

, et al. Altered microbiota, fecal lactate, and fecal bile acids in dogs with gastrointestinal disease. PLoS One 2019; 14: e0224454.

109.

Sirtori

Motta Ade

Brandelli

. Mode of action of antimicrobial peptide P45 on Listeria monocytogenes. J Basic Microbiol 2008; 48: 393–400.

110.

Hancock

. Peptide antibiotics. Lancet 1997; 349: 418–422.

111.

Fan

Sun

Zhou

, et al. DRAMP: a comprehensive data repository of antimicrobial peptides. Sci Rep 2016; 6: 24482.

112.

Wong

. Shaping the gut microbiome from the pancreas. Sci Signal 2017; 10: eaan3016.

113.

Deng

Y-Y

Shamoon

, et al. Cathelicidin-related antimicrobial peptide modulates the severity of acute pancreatitis in mice. Mol Med Rep 2016; 13: 3881–3885.

114.

Zhao

Chen

, et al. GPR43 mediates microbiota metabolite SCFA regulation of antimicrobial peptide expression in intestinal epithelial cells via activation of mTOR and STAT3. Mucosal Immunol 2018; 11: 752–762.

115.

Huang

Chen

Wang

, et al. Dysbiosis of intestinal microbiota and decreased antimicrobial peptide level in Paneth cells during hypertriglyceridemia-related acute necrotizing pancreatitis in rats. Front Microbiol 2017; 8: 776.

116.

Bevins

Salzman

. Paneth cells, antimicrobial peptides and maintenance of intestinal homeostasis. Nat Rev Microbiol 2011; 9: 356–368.

117.

Clevers

Bevins

. Paneth cells: maestros of the small intestinal crypts. Annu Rev Physiol 2013; 75: 289–311.

118.

Eriguchi

Nakamura

Hashimoto

, et al. Decreased secretion of Paneth cell α-defensins in graft-versus-host disease. Transpl Infect Dis 2015; 17: 702–706.

119.

Mukherjee

Zheng

Derebe

, et al. Antibacterial membrane attack by a pore-forming intestinal C-type lectin. Nature 2014; 505: 103–107.

120.

Cash

Whitham

Behrendt

, et al. Symbiotic bacteria direct expression of an intestinal bactericidal lectin. Science 2006; 313: 1126–1130.

121.

Vaishnava

Yamamoto

Severson

, et al. The antibacterial lectin RegIIIgamma promotes the spatial segregation of microbiota and host in the intestine. Science 2011; 334: 255–258.

122.

Menendez

Willing

Montero

, et al. Bacterial stimulation of the TLR-MyD88 pathway modulates the homeostatic expression of ileal Paneth cell α-defensins. J Innate Immun 2013; 5: 39–49.

123.

Brandl

Plitas

Schnabl

, et al. MyD88-mediated signals induce the bactericidal lectin RegIII gamma and protect mice against intestinal Listeria monocytogenes infection. J Exp Med 2007; 204: 1891–1900.

124.

Vaishnava

Behrendt

Ismail

, et al. Paneth cells directly sense gut commensals and maintain homeostasis at the intestinal host-microbial interface. Proc Natl Acad Sci USA 2008; 105: 20858–20863.

125.

Salzman

Hung

Haribhai

, et al. Enteric defensins are essential regulators of intestinal microbial ecology. Nat Immunol 2010; 11: 76–83.

126.

Satoh

Habara

Ono

, et al. Carbamylcholine- and catecholamine-induced intracellular calcium dynamics of epithelial cells in mouse ileal crypts. Gastroenterology 1995; 108: 1345–1356.

127.

Ayabe

Satchell

Wilson

, et al. Secretion of microbicidal alpha-defensins by intestinal Paneth cells in response to bacteria. Nat Immunol 2000; 1: 113–118.

128.

Adolph

Mayr

Grabherr

, et al. Pancreas-microbiota cross talk in health and disease. Annu Rev Nutr 2019; 39: 249–266.

129.

Kershaw

Flier

. Adipose tissue as an endocrine organ. J Clin Endocrinol Metab 2004; 89: 2548–2556.

130.

Lee

Pratley

. The evolving role of inflammation in obesity and the metabolic syndrome. Curr Diab Rep 2005; 5: 70–75.

131.

Bastard

J-P

Maachi

Lagathu

, et al. Recent advances in the relationship between obesity, inflammation, and insulin resistance. Eur Cytokine Netw 2006; 17: 4–12.

132.

Lloret Linares

Pelletier

Czernichow

, et al. Acute pancreatitis in a cohort of 129 patients referred for severe hypertriglyceridemia. Pancreas 2008; 37: 13–12.

133.

Deng

Xue

Xia

, et al. Effect of admission hypertriglyceridemia on the episodes of severe acute pancreatitis. World J Gastroenterol 2008; 14: 4558–4561.

134.

Guo

Zhang

, et al. Hypertriglyceridemia-induced acute pancreatitis: progress on disease mechanisms and treatment modalities. Discov Med 2019; 27: 101–109.

135.

Turnbaugh

Ley

Mahowald

, et al. An obesity-associated gut microbiome with increased capacity for energy harvest. Our Nat 2006; 444: 1027–1031.

136.

Santos-Marcos

Perez-Jimenez

Camargo

. The role of diet and intestinal microbiota in the development of metabolic syndrome. J. Nutr. Biochem 2019; 70: 1–27.

137.

Mössner

Bödeker

Kimura

, et al. Isolated rat pancreatic acini as a model to study the potential role of lipase in the pathogenesis of acinar cell destruction. Int. J. Pancreatol 1992; 12: 285–296.

138.

Dettelbach

Deftos

Stewart

. Intraperitoneal free fatty acids induce severe hypocalcemia in rats: a model for the hypocalcemia of pancreatitis. J Bone Miner Res 1990; 5: 1249–1255.

139.

Navina

Acharya

DeLany

, et al. Lipotoxicity causes multisystem organ failure and exacerbates acute pancreatitis in obesity. Sci Transl Med 2011; 3: 107ra110.

140.

Bäckhed

Ding

Wang

, et al. The gut microbiota as an environmental factor that regulates fat storage. Proc. Natl. Acad. Sci. U.S.A 2004; 101: 15718–15723.

141.

Yuan

Giovannucci

Larsson

. Gallstone disease, diabetes, calcium, triglycerides, smoking and alcohol consumption and pancreatitis risk: Mendelian randomization study. NPJ Genomic Med 2021; 6: 27.

142.

Shalbueva

Mareninova

Gerloff

, et al. Effects of oxidative alcohol metabolism on the mitochondrial permeability transition pore and necrosis in a mouse model of alcoholic pancreatitis. Gastroenterology 2013; 144: 437–446.e6.

143.

Apte

Pirola

Wilson

. Mechanisms of alcoholic pancreatitis. J. Gastroenterol. Hepatol 2010; 25: 1816–1826.

144.

Heier

Xie

Zimmermann

. Nonoxidative ethanol metabolism in humans-from biomarkers to bioactive lipids. IUBMB Life 2016; 68: 916–923.

145.

Rendon

Akhtar

, et al. Interleukin-22 modulates gut epithelial and immune barrier functions following acute alcohol exposure and burn injury. Shock 2013; 39: 11–18.

146.

Engen

Green

Voigt

, et al. The gastrointestinal microbiome: alcohol effects on the composition of intestinal microbiota. Alcohol Res 2015; 37: 223–236.

147.

Sublette

Cross

Korcarz

, et al. Effects of smoking and smoking cessation on the intestinal microbiota. J. Clin. Med 2020; 9: 2963.

148.

Kim

Paik

Lee

, et al. Association between increased breath hydrogen methane concentration and prevalence of glucose intolerance in acute pancreatitis. J. Breath Res 2020; 14: 026006.

149.

Ansari

Husain

Rizvi

, et al. Role of transcription factors in steatohepatitis and hypertension after ethanol: the epicenter of metabolism. Biomolecules 2016; 6: 29.

150.

Sonnenberg

Fouser

Artis

. Border patrol: regulation of immunity, inflammation and tissue homeostasis at barrier surfaces by IL-22. Nat. Immunol 2011; 12: 383–390.

151.

Sonnenberg

Fouser

Artis

. Functional biology of the IL-22-IL-22R pathway in regulating immunity and inflammation at barrier surfaces. Adv. Immunol 2010; 107: 1–29.

152.

Gong

Zhao

M-H

, et al. Role of interleukin-22 in inflammatory bowel disease. World J Gastroenterol 2014; 20: 18177–18188.

153.

González-Reimers

Santolaria-Fernández

Martín-González

, et al. Alcoholism: a systemic proinflammatory condition. World J. Gastroenterol 2014; 20: 14660–14671.

154.

Hendrikx

Duan

Wang

, et al. Bacteria engineered to produce IL-22 in intestine induce expression of REG3G to reduce ethanol-induced liver disease in mice. Gut 2019; 68: 1504–1515.

155.

Czakó

Hegyi

Rakonczay

Jr , et al. Interactions between the endocrine and exocrine pancreas and their clinical relevance. Pancreatology 2009; 9: 351–359.

156.

Das

Singh

Phillips

, et al. Newly diagnosed diabetes mellitus after acute pancreatitis: a systematic review and meta-analysis. Gut 2014; 63: 818–831.

157.

Khan

Ikram

Park

, et al. Pathology, risk factors, and oxidative damage related to type 2 diabetes-mediated Alzheimer's disease and the rescuing effects of the potent antioxidant anthocyanin. Oxid. Med. Cell Longev 2021; 2021: 4051207.

158.

Halangk

Lerch

. Early events in acute pancreatitis. Clin. Lab. Med 2005; 25: 1–15.

159.

Kamboj

Sandhir

. Protective effect of N-acetylcysteine supplementation on mitochondrial oxidative stress and mitochondrial enzymes in cerebral cortex of streptozotocin-treated diabetic rats. Mitochondrion 2011; 11: 214–222.

160.

Jhun

Yoon

. High-glucose stimulation increases reactive oxygen species production through the calcium and mitogen-activated protein kinase-mediated activation of mitochondrial fission. Antioxid. Redox Signal 2011; 14: 425–437.

161.

Ciciliot

Albiero

Campanaro

, et al. Interplay between gut microbiota and p66Shc affects obesity-associated insulin resistance. FASEB J 2018; 32: 4004–4015.

162.

Kang

Chen

Xie

, et al. The receptor for advanced glycation end products activates the AIM2 inflammasome in acute pancreatitis. J. Immunol 2016; 196: 4331–4337.

163.

Yan

Schmidt

Anderson

, et al. Enhanced cellular oxidant stress by the interaction of advanced glycation end products with their receptors/binding proteins. J. Biol. Chem 1994; 269: 9889–9897.

164.

Halliwell

. The wanderings of a free radical. Free Radic. Biol. Med 2009; 46: 531–542.

165.

Zhang

Xin

, et al. Extract of ice plant (Mesembryanthemum crystallinum) ameliorates hyperglycemia and modulates the gut microbiota composition in type 2 diabetic Goto-Kakizaki rats. Food Funct 2019; 10: 3252–3261.

166.

Qin

Cai

, et al. A metagenome-wide association study of gut microbiota in type 2 diabetes. Nature 2012; 490: 55–60.

167.

Tilg

Zmora

Adolph

, et al. The intestinal microbiota fuelling metabolic inflammation. Nat Rev Immunol 2020; 20: 40–54.

168.

Thaiss

Levy

Grosheva

, et al. Hyperglycemia drives intestinal barrier dysfunction and risk for enteric infection. Science 2018; 359: 1376–1383.

169.

Arora

Behl

Sehgal

, et al. Unravelling the involvement of gut microbiota in type 2 diabetes mellitus. Life Sci 2021; 273: 119311.

170.

Noel

Braun

Patterson

, et al. Increased risk of acute pancreatitis and biliary disease observed in patients with type 2 diabetes: a retrospective cohort study. Diabetes Care 2009; 32: 834–838.

171.

Lai

Muo

Liao

, et al. Risk of acute pancreatitis in type 2 diabetes and risk reduction on anti-diabetic drugs: a population-based cohort study in Taiwan. Am J Gastroenterol 2011; 106: 1697–1704.

172.

Girman

Kou

Cai

, et al. Patients with type 2 diabetes mellitus have higher risk for acute pancreatitis compared with those without diabetes. Diabetes Obes Metab 2010; 12: 766–771.

173.

Rakonczay

Jr Hegyi

Takács

, et al. The role of NF-kappaB activation in the pathogenesis of acute pancreatitis. Gut 2008; 57: 259–267.

174.

Zhang

Feng

, et al. PGRN exerts inflammatory effects via SIRT1-NF-κB in adipose insulin resistance. J Mol Endocrinol 2020; 64: 181–193.

175.

Phillips

Abu-Zidan

Bonham

, et al. Amylin and severe acute pancreatitis. Pancreas 2000; 20: 105–106.

176.

Tukiainen

Kylanpaa

Ebeling

, et al. Leptin and adiponectin levels in acute pancreatitis. Pancreas 2006; 32: 211–214.

177.

Gillies

Pendharkar

Asrani

, et al. Interleukin-6 is associated with chronic hyperglycemia and insulin resistance in patients after acute pancreatitis. Pancreatology 2016; 16: 748–755.

178.

Wei

Yang

Rey

, et al. Fatty acid synthase modulates intestinal barrier function through palmitoylation of mucin 2. Cell Host Microbe 2012; 11: 140–152.

179.

Koksal

Boga

Alkim

, et al. Insulin resistance as a novel risk factor for post-ERCP pancreatitis: a pilot study. Dig Dis Sci 2016; 61: 2397–2405.

180.

Cho

Huh

Yoo

, et al. HOMA-estimated insulin resistance as an independent prognostic factor in patients with acute pancreatitis. Sci Rep 2019; 9: 14894.

181.

Upadhyaya

Banerjee

. Type 2 diabetes and gut microbiome: at the intersection of known and unknown. Gut Microbes 2015; 6: 85–92.

182.

Ngo

Abo

Maxim

, et al. A cytokine network involving IL-36γ, IL-23, and IL-22 promotes antimicrobial defense and recovery from intestinal barrier damage. Proc Natl Acad Sci U S A 2018; 115: E5076–e5085.

183.

Shih

Cox

Kljavin

, et al. Homeostatic IL-23 receptor signaling limits Th17 response through IL-22-mediated containment of commensal microbiota. Proc Natl Acad Sci U S A 2014; 111: 13942–13947.

184.

Al-Hariri

Eldin

Hashim

, et al. Propolis modulates inflammatory mediators and improves histopathology in male rats with L-arginine-induced acute pancreatitis. Sultan Qaboos Univ Med J 2019; 19: e103–e107.

185.

Riva

Griglio

Serafini

, et al. Pyrtriazoles, a novel class of store-operated calcium entry modulators: discovery, biological profiling, and in vivo proof-of-concept efficacy in acute pancreatitis. J Med Chem 2018; 61: 9756–9783.

186.

Waldron

Chen

Pham

, et al. The Orai Ca²⁺ channel inhibitor CM4620 targets both parenchymal and immune cells to reduce inflammation in experimental acute pancreatitis. J Physiol 2019; 597: 3085–3105.

187.

Xiong

Zhang

, et al. Okra pectin relieves inflammatory response and protects damaged intestinal barrier in caerulein-induced acute pancreatic model. J Sci Food Agric 2021; 101: 863–870.

188.

Hooijmans

de Vries

Rovers

, et al. The effects of probiotic supplementation on experimental acute pancreatitis: a systematic review and meta-analysis. PLoS One 2012; 7: e48811.

189.

Bongaerts

GPA

Severijnen

RSVM

. A reassessment of the Propatria study and its implications for probiotic therapy. Nat Biotechnol 2016; 34: 55–63.

190.

Patel

Bhatia

, et al. Gut microbiome in acute pancreatitis: a review based on current literature. World J Gastroenterol 2021; 27: 5019–5036.

191.

Han

, et al. Saikosaponin A-Induced gut Microbiota changes attenuate severe acute pancreatitis through the activation of Keap1/Nrf2-ARE antioxidant signaling. Oxid Med Cell Longev 2020; 2020: 9217219.

192.

Zhang

Zhao

Zhang

, et al. Structural changes of gut microbiota during berberine-mediated prevention of obesity and insulin resistance in high-fat diet-fed rats. PLoS One 2012; 7: e42529.

193.

Fan

Guo

Wang

, et al. [Effect of berberine on insulin resistance in diabetic rats]. Zhongguo Ying Yong Sheng Li Xue Za Zhi 2020; 36: 561–564.

194.

Tarasiuk

Pawlik

Fichna

. [Berberine as a potential therapeutic agent in the treatment of acute pancreatitis]. Postepy Biochem 2019; 65: 224–230.

195.

Meng

J-B

Jiao

Y-N

, et al. Electro-acupuncture attenuates inflammatory responses and intraabdominal pressure in septic patients: a randomized controlled trial. Medicine 2018; 97: e0555.

196.

Zheng

Valdez

Danilenko

, et al. Interleukin-22 mediates early host defense against attaching and effacing bacterial pathogens. Nat. Med 2008; 14: 282–289.

197.

Zindl

Lai

Lee

, et al. IL-22-producing neutrophils contribute to antimicrobial defense and restitution of colonic epithelial integrity during colitis. Proc Natl Acad Sci U S A 2013; 110: 12768–12773.

198.

Bernhard

. Choline in cystic fibrosis: relations to pancreas insufficiency, enterohepatic cycle, PEMT and intestinal microbiota. Eur J Nutr 2021; 60: 1737–1759.

199.

Wang

Liu

, et al. The gut-lung axis in severe acute Pancreatitis-associated lung injury: the protection by the gut microbiota through short-chain fatty acids. Pharmacol Res 2022; 182: 106321.

200.

Wang

Xiao

, et al. Protective effects of different Bacteroides vulgatus strains against lipopolysaccharide-induced acute intestinal injury, and their underlying functional genes. J Adv Res 2022; 36: 27–37.

201.

Zhang

Gao

Sakandar

, et al. Gut dysbiosis in pancreatic diseases: A causative factor and a novel therapeutic target. Front Nutr 2022; 9: 814269.

202.

Besselink

van Santvoort

Renooij

, et al. Intestinal barrier dysfunction in a randomized trial of a specific probiotic composition in acute pancreatitis. Ann Surg 2009; 250: 712–719.

203.

Rahman

Ammori

Holmfield

, et al. Intestinal hypoperfusion contributes to gut barrier failure in severe acute pancreatitis. J Gastrointest Surg 2003; 7: 26–36.

204.

Besselink

van Santvoort

Buskens

, et al. Probiotic prophylaxis in predicted severe acute pancreatitis: a randomised, double-blind, placebo-controlled trial. Lancet 2008; 371: 651–659.

205.

Lutgendorff

Trulsson

van Minnen

, et al. Probiotics enhance pancreatic glutathione biosynthesis and reduce oxidative stress in experimental acute pancreatitis. Am J Physiol Gastrointest Liver Physiol 2008; 295: G1111–G1121.

206.

Lutgendorff

Nijmeijer

Sandström

, et al. Probiotics prevent intestinal barrier dysfunction in acute pancreatitis in rats via induction of ileal mucosal glutathione biosynthesis. PLoS One 2009; 4: e4512.

207.

Zhu

Mei

, et al. Alteration of gut microbiota in acute pancreatitis and associated therapeutic strategies. Biomed Pharmacother 2021; 141: 111850.

208.

Tian

Liu

, et al. Supplemented use of pre-, pro-, and synbiotics in severe acute pancreatitis: an updated systematic review and meta-analysis of 13 randomized controlled trials. Front Pharmacol 2018; 9: 690.

209.

Mei

Huang

, et al. Pretreatment with chitosan oligosaccharides attenuate experimental severe acute pancreatitis via inhibiting oxidative stress and modulating intestinal homeostasis. Acta Pharmacol Sin 2021; 42: 942–953.

210.

Xie

Guo

, et al. Bifidobacterium spp. and their metabolite lactate protect against acute pancreatitis via inhibition of pancreatic and systemic inflammatory responses. Gut Microbes 2022; 14: 2127456.

211.

Banks

. Acute pancreatitis: landmark studies, management decisions, and the future. Pancreas 2016; 45: 633–640.

212.

Ammori

. Role of the gut in the course of severe acute pancreatitis. Pancreas 2003; 26: 122–129.

213.

Kotzampassi

Giamarellos-Bourboulis

. Probiotics for infectious diseases: more drugs, less dietary supplementation. Int. J. Antimicrob. Agents 2012; 40: 288–296.

214.

Surana

Kasper

. Moving beyond microbiome-wide associations to causal microbe identification. Our Nat 2017; 552: 244–247.

215.

Sun

, et al. Effects of early enteral nutrition on immune function of severe acute pancreatitis patients. World J Gastroenterol 2013; 19: 917–922.

216.

Fishman

Levy

Alli

, et al. The intestinal mucus layer is a critical component of the gut barrier that is damaged during acute pancreatitis. Shock 2014; 42: 264–270.

217.

Zmora

Zilberman-Schapira

Suez

, et al. Personalized gut mucosal colonization resistance to empiric probiotics is associated with unique host and microbiome features. Cell 2018; 174: 1388–1405.e21.

218.

Cohen

. Probiotic safety-no guarantees. JAMA Intern Med 2018; 178: 1577–1578.

219.

Sun

Dai

, et al. Indigo naturalis alleviates dextran sulfate sodium-induced colitis in rats via altering gut Microbiota. Front Microbiol 2020; 11: 731.

220.

Song

, et al. Mercury sulfide-containing Hua-Feng-Dan and 70W (Rannasangpei) protect against LPS plus MPTP-induced neurotoxicity and disturbance of gut microbiota in mice. J Ethnopharmacol 2020; 254: 112674.

221.

Hong

Zheng

, et al. Integrated metagenomic and metabolomic analyses of the effect of Astragalus polysaccharides on alleviating high-fat diet-induced metabolic disorders. Front Pharmacol 2020; 11: 833.

222.

Miao

, et al. Regulating gut flora dysbiosis in obese mice by electroacupuncture. Am J Chin Med 2018; 46: 1481–1497.

Gut microbiota interacts with inflammatory responses in acute pancreatitis

Abstract

Keywords

Introduction

The influence of intestinal flora changes on the occurrence and development of AP

Intestinal flora migration influences the pancreatic microenvironment in AP

Intestinal microbiota attenuates the severity of AP

The influence of AP on intestinal flora changes

Acute pancreatitis-associated gut barrier and functional damage facilitate intestinal flora migration

Effects of secretion of cell damage factors on intestinal flora in AP

Pancreatic exocrine deficiency affects the composition and diversity of GM in AP

Antimicrobial peptide changes in AP-affected intestinal flora

Risk factors that influence the GM and AP

Obesity and hyperlipidemia

Alcohol

High glucose and insulin resistance

Curative substances influence both AP and GM

Future research prospects

Footnotes

Acknowledgements

Declarations

References